Log in to your Inderes Free account to see all free content on this page.
CellaVision
245 SEK -2.39%1,502 investors are following this company
CellaVision is active in medical technology. The company's operations develop and market image analysis systems for diagnosing blood and other body fluids. The products are intended to replace traditional microscope analysis. Operations are conducted on a global level, primarily in the Nordic countries, Europe and North America, where customers consist of research institutes. The head office is located in Lund.
Revenue
-
EBIT %
-
P/E
44.87
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Stockholm
CEVI
Daily low / high price
245 / 250.5
SEK
Market cap
5.84B SEK
Turnover
81.09K SEK
Volume
327
Latest videos
Financial calendar
Interim report
24.10.2024
Annual report
06.02.2025
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
William Demant Invest | 19.9 % | 19.9 % |
Grenlunden CEVI AB | 10.0 % | 10.0 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
![CellaVision, Audiocast with teleconference, Q2'24](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/d7b70acb-042d-482f-82ad-adbc1f2e6132.png)
CellaVision, Audiocast with teleconference, Q2'24
Solid Quarter and Growth in APAC
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Invitation to Presentation of the CellaVision Report for the Second Quarter 2024 on July 19, at 11:00 CEST
Bulletin from the Annual General Meeting of CellaVision AB (publ)
Redeye: Cellavision - Trend is still their friend
![CellaVision, Audiocast with teleconference, Q1, 2024](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/a68533b7-87f3-46d8-b49d-a765fa3c0fb8.png)
CellaVision, Audiocast with teleconference, Q1, 2024
A Solid Start to the Year
Invitation to Presentation of the CellaVision Report for the First Quarter 2024 on April 25, at 11:00 CEST
CellaVision publishes its 2023 Annual and Sustainability Report
NOTICE OF ANNUAL GENERAL MEETING IN CELLAVISION AB (publ)
Redeye: Cellavision Q4 - Firing on all cylinders towards the year-end
![CellaVision, Audiocast with teleconference, Q4, 2023](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/cc15b888-9b5c-44d8-a5ec-801257bdbed9.png)
CellaVision, Audiocast with teleconference, Q4, 2023
Market Momentum All-Time High Quarterly Sales
CellaVision and Sysmex Sign Strategic Alliance Agreement
Invitation to Presentation of the CellaVision Year-end Report for 2023 on February 7, at 11:00 CET
Nomination Committee for the CellaVision Annual General Meeting 2024
Redeye: Cellavision Q3 2023 - Normalization in progress
![CellaVision, Audiocast with teleconference, Q3, 2023](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/7b9dc5a9-ec75-4456-935d-e98d7fa0caf1.png)